LTRN•benzinga•
EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial
Summary
Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 5, 2025 by benzinga